

Special Issue

Advancements in Treatment Approaches for AML

Message from the Guest Editors

We invite your contributions to the Special Issue on "Advancements in Treatment Approaches for AML." This issue focuses on advancements in diagnosis, prognosis, and treatment strategies for acute myeloid leukemia (AML). We seek original research articles and reviews exploring novel diagnostic and treatment strategies across various settings. Collaborating with experts, we aim to ensure the success of this endeavor. Potential research areas include molecular pathogenesis, diagnostic algorithms, clinical trials of innovative therapies, novel therapeutic targets and immunotherapy, guideline recommendations, and strategies in allogeneic hematopoietic stem cell transplantation. All articles will undergo rigorous peer review to ensure scientific quality and relevance. Contributions from researchers, clinicians, and oncology experts are encouraged. Your submissions will contribute to the collective understanding and progress in AML treatment. For questions or assistance, please reach out to us. We are here to support your participation. Thank you for your attention, and we look forward to your valuable contributions.

Guest Editors

Dr. Semra Aydin

Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany

Dr. Raheel Iftikhar

Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan

Deadline for manuscript submissions

31 March 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/201468

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)